THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [SUPP-1] ID: TIP-MED-000451 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Adrenaline (Epinephrine) Tartrate IP [SUPP-1] — IM Anaphylaxis 1:1,000 Emergency Kit Monograph

Active Ingredient / Scientific Identity: Adrenaline • Class: Non-Selective Alpha-1, Alpha-2, Beta-1 & Beta-2 Adrenergic Receptor Agonist (Endogenous Catecholamine)

⚖️ Compare Profile
Generic / Entity NameAdrenaline (Epinephrine) Tartrate IP ([SUPP-1])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassNon-Selective Alpha-1, Alpha-2, Beta-1 & Beta-2 Adrenergic Receptor Agonist (Endogenous Ca
Available Dosage FormsStandard hospital formulary strengths
Regulatory ClassificationSchedule H Prescription Drug • NLEM 2022 Core Emergency Medicine • ISMP High-Alert
Key Warning & Review DateHigh-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug • NLEM 2022 Core Emerge🚨 Clinically High-Alert: Independent Dose & Route Verification Required👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Adrenaline (Epinephrine) Tartrate IP (TIP-MED-000451, Reference Code [SUPP-1]) is classified under Supplementary Emergency Resuscitation & Anaphylaxis Module (Edition 2.7 Appendix B) as a Non-Selective Alpha-1, Alpha-2, Beta-1 & Beta-2 Adrenergic Receptor Agonist (Endogenous Catecholamine). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Emergency Medicine • ISMP High-Alert.

Verified Indian Market Examples / Compendial Status:
Hospital & critical-care generic reference; verify institutional protocol and CDSCO package insert.
Hospital & critical-care generic reference; verify institutional protocol and CDSCO package insert.
Dosage Forms & Available Strengths:
Standard hospital formulary strengths
Routes: Intravenous / Parenteral / Oral

3. Mechanism of Action & Pharmacodynamics

Targeted critical-care pharmacological mechanism.

4. Therapeutic Indications & Evidence-Supported Uses

  • Hospital critical care and specialist management per clinical protocol.

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Specialist hospital dosing only; verify renal/hepatic function and institutional protocol.

Administration & Meal Timing: Administer under qualified healthcare supervision.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Metabolism & Biotransformation:
Hepatic and/or extrahepatic clearance.
Elimination & Renal Adjustment:
Evaluate eGFR/CrCl before and during therapy.
Hepatic Impairment Considerations:
Evaluate hepatic transaminases and bilirubin.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Known hypersensitivity to active ingredient or formulation excipients.

Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Refer to institutional monograph and package insert.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Verify co-administered critical-care medications for pharmacokinetic/pharmacodynamic interactions.

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.

Pharmacist Patient Counselling Points:

  • Explain treatment purpose, monitoring schedule, and warning symptoms to patient/caregiver.

Storage, Stability & Dispensing Safeguards: Store per official IP 2022 / manufacturer label instructions.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

Related Companion Monograph: See also the primary clinical reference monograph at /medicine/12-32-cmp175-adrenaline-epinephrine-tartrate-ip-supplementary-eme/ for complementary therapeutic comparison and dosing context.